Continuum Advisory’s Royalty Pharma RPRX Stock Holding History

Continuum Advisory’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-428	Closed	-$13.3K	–	1328
2025 Q1	$13.3K	Buy	+428	New	+$13.6K	﹤0.01%	929

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

Continuum Advisory's RPRX Position: Q2 2025 in Review

Continuum Advisory sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 428 shares — an estimated $13.3K sold.

Continuum Advisory first reported a position in RPRX in Q1 2025 and held it in 1 quarter. The position peaked at $13.3K in Q1 2025. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

Continuum Advisory reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
Continuum Advisory sold 428 Royalty Pharma shares in Q2 2025, an estimated $13.3K.
Continuum Advisory first reported a position in Royalty Pharma in Q1 2025 and held it in 1 quarter.
Continuum Advisory's Royalty Pharma position peaked at $13.3K in Q1 2025.
455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.